Trials / Recruiting
RecruitingNCT05296356
OSU6162 in Bipolar Depression (OBID)
OSU6162 in Bipolar Depression: An Open-label, Flexible Dose Study (OBID)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- Sponsor
- Göteborg University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
An explorative, open label, single armed, flexible dose, single center, phase IIa study of 8 weeks, initiated in subjects with bipolar depression. The study will consist of 9 visits and 1 safety visit. Subjects with a primary diagnosis of bipolar disorder (type 1 or 2) currently in an acute depressive phase (i.e. bipolar depression) and being on stable medication with at least one mood stabilizer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OSU6162 | OSU6162 |
Timeline
- Start date
- 2021-10-25
- Primary completion
- 2026-05-31
- Completion
- 2027-05-31
- First posted
- 2022-03-25
- Last updated
- 2025-03-21
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT05296356. Inclusion in this directory is not an endorsement.